Myomo Reports Record Third Quarter Financial and Operating Results

$9.2 million in revenue, raises full-year revenue guidance 225 MyoPro® authorizations and orders with 316 patients in backlog at quarter end 645 additions to the pipeline result in 1,263 patients in the pipeline as of September 30, 2024

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced financial results for the three and nine months ended September 30, 2024.

Financial and operating highlights for the third quarter of 2024 include the following (all comparisons are with the third quarter of 2023 unless otherwise indicated):

• Product and total revenue was a record $9.2 million, up 83% and 81%, respectively;
• Revenue units were a record 161, up 35%;
• Orders and insurance authorizations were received for a record 225 MyoPro units, up 44%;
• Backlog, which represents insurance authorizations and orders received but not yet converted to revenue, was a record 316 units as of September 30, 2024, up 71%;
• A record 645 new candidates were added to the patient pipeline, up 69%;
• There were 1,263 MyoPro candidates in the patient pipeline as of September 30, 2024, up 21%;
• Gross margin was 75.4%, up 670 basis points, with gross margin on product revenues up 700 basis points;
• Cost per pipeline add was $1,618, down 25%; and
• The Company launched its orthotics and prosthetics ("O&P") channel program at the American Orthotic and Prosthetic Association (AOPA) National Assembly in September, and began training O&P clinics to provide the MyoPro to their patients.

Management Commentary

“Myomo delivered a second consecutive quarter of record financial and operating results as we emphasized outreach and education to the Medicare population regarding the benefits of the MyoPro, as well as an unwavering commitment to efficiency, quality and improving patient outcomes across our organization", said Paul R. Gudonis, Myomo's chairman and chief executive officer. "Our focus has been on accelerating revenue growth though our direct provider sales channel and laying the groundwork for growth in the O&P channel in 2025 and beyond. Demonstrable progress was made on both of these areas during the third quarter."

Financial Results

 

For the Three Months Ended September 30,

 

Period- to-Period Change

 

For the Nine Months Ended September 30,

 

Period- to-Period Change

 

 

2024

 

2023

 

$

 

%

 

2024

 

2023

 

$

 

%

 

Product revenue

$

9,207,586

 

$

5,029,523

 

$

4,178,063

 

 

83

%

$

20,482,742

 

$

12,719,855

 

$

7,762,887

 

 

61

%

License revenue

 

—

 

 

50,000

 

 

(50,000

)

 

(100

)%

 

—

 

 

1,764,920

 

 

(1,764,920

)

 

(100

)%

Total revenue

 

9,207,586

 

 

5,079,523

 

 

4,128,063

 

 

81

%

 

20,482,742

 

 

14,484,775

 

 

5,997,967

 

 

41

%

Cost of revenue

 

2,262,031

 

 

1,590,675

 

 

671,356

 

 

42

%

 

5,912,632

 

 

4,407,270

 

 

1,505,362

 

 

34

%

Gross profit

$

6,945,555

 

$

3,488,848

 

$

3,456,707

 

 

99

%

$

14,570,110

 

$

10,077,505

 

$

4,492,605

 

 

45

%

Gross margin %

 

75.4

%

 

68.7

%

 

 

 

6.7

%

 

71.1

%

 

69.6

%

 

 

 

1.5

%

Revenue for the third quarter of 2024 was $9.2 million, up 81% compared with the third quarter of 2023. Product revenue increased 83% compared with the same period a year ago, driven by growth in revenue units and by a higher average selling price ("ASP"). Myomo recognized revenue on 161 MyoPro units in the third quarter of 2024, up 35% over the same quarter a year ago. ASP was approximately $57,200 in the third quarter, up 35%. A portion of the increase in ASP reflects payments from supplemental insurance payers on revenue units recognized in a prior period. Excluding these payments, ASP was approximately $52,700, up 23%. Effective July 1, 2024, revenue for Medicare Part B patients is being recognized at the time of product delivery for the amount expected to be paid for each patient. Revenue from patients with Medicare Part B represented 55% of revenue in the third quarter. Year-to-date revenue was $20.5 million, up 41% compared with the same period a year ago. Year-to-date product revenue was up 61% compared with the first nine months of 2023.

Gross margin for the third quarter of 2024 was 75.4%, compared with 68.7% for the third quarter of 2023. The increase was driven primarily by a higher ASP. Gross margin on product revenues for the third quarter of 2023 was 68.4%. Year-to-date gross margin was 71.1% compared with 69.6% for the same period a year ago. Gross margin on product revenue for the first nine months of 2023 was 65.4%.

Operating expenses for the third quarter of 2024 were $7.9 million, an increase of 43% compared with the third quarter of 2023. The increase was driven primarily by higher payroll expense due to additional headcount to support the Company's engineering efforts, as well as the addition of field clinical and reimbursement capacity and incentive compensation accruals. Advertising costs of $1.0 million were up 23% over the third quarter of 2023. Cost per pipeline add was $1,618, a decrease of 25% compared with the third quarter of 2023. Year-to-date operating expenses were $20.5 million, an increase of 29% compared with the same period a year ago.

Operating loss for the third quarter of 2024 was $1.0 million, compared with $2.0 million for the third quarter of 2023. Net loss for the third quarter of 2024 was $1.0 million, or $0.03 per share, compared with a net loss of $2.0 million, or $0.06 per share, for the third quarter of 2023. Year-to-date operating loss was $6.0 million, compared with an operating loss of $5.8 million for the same period a year ago. Year-to-date net loss was $5.9 million, or $0.16 per share, compared with a net loss of $5.7 million, or $0.21 per share, for the same period a year ago.

Adjusted EBITDA for the third quarter of 2024 was $(0.6) million, compared with $(1.7) million for the third quarter of 2023. Year-to-date Adjusted EBITDA was $(5.3) million, compared with $(4.9) million for the same period a year ago. A reconciliation of GAAP net loss to this non-GAAP financial measure appears below.

Operations Update

The patient pipeline was 1,263 patients as of September 30, 2024, compared with 1,046 as of September 30, 2023, an increase of 21%. A record 645 patients were added to the pipeline during the third quarter of 2024, an increase of 69% compared with the same period a year ago. The Company generated a record 225 authorizations and orders in the third quarter of 2024, an increase of 44% compared with the same period a year ago. As a result, backlog was a record 316 patients as of September 30, 2024, an increase of 71% compared with September 30, 2023.

Cash Position

Cash, cash equivalents and restricted cash as of September 30, 2024 were $7.0 million. Cash used in operating activities was $1.5 million for the third quarter of 2024, compared with $1.7 million for the third quarter of 2023. Cash used in operating activities in the third quarter of 2024 was impacted by a payment delay during the last two to three weeks of the quarter from the Centers for Medicare & Medicaid Services ("CMS") due to a transition from check payments to electronic funds transfer, which is expected to speed up payments going forward. The delayed payments were subsequently received in October.

Business Outlook

“We are positioned to deliver sequential revenue growth in the fourth quarter due to the strength of our backlog," added Mr. Gudonis. "As a result, we expect fourth quarter revenue to be in the range of $9.5 million to $10.5 million, resulting in full year revenue of $30 million to $31 million, up from our previous guidance of $28 million to $30 million."

"We believe our objective of reaching operating cash flow breakeven in the fourth quarter is achievable. We also expect to approach Adjusted EBITDA breakeven in the fourth quarter. We expect a moderation in cash used to fund growth in working capital, as we collected in the fourth quarter the Medicare payments that were delayed from the third quarter," said David Henry, Myomo's chief financial officer. "Moderation in the growth of working capital in the fourth quarter is predicated on minimizing growth in days sales outstanding and receipt of a contractual reimbursement from the landlord for initial costs associated with the lease on our new facility."

Conference Call and Webcast

Myomo will hold a conference call today at 4:30 p.m. Eastern time to discuss these results and answer questions. Participants are encouraged to pre-register for the call at this link. Callers who pre-register will receive a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time up to and after the start of the call. Those unable to pre-register may participate by dialing 844-707-6932 (U.S.) or 412-317-9250 (International). A webcast of the call will also be available at Myomo’s Investor Relations page at http://ir.myomo.com/.

A replay of the webcast will be available beginning approximately one hour after the completion of the live conference call at http://ir.myomo.com/. A dial-in replay of the call will be available until November 20, 2024 at 877-344-7529 (U.S. toll-free), 855-669-9658 (Canada toll-free) or 412-317-0088 (International), with passcode 3377340.

Non-GAAP Financial Measures

Myomo is providing financial information that has not been prepared in accordance with generally accepted accounting principles in the United States, or GAAP. This information includes Adjusted EBITDA. This non-GAAP financial measure is not in accordance with, or an alternative for, GAAP and may be different from similar non-GAAP financial measures used by other companies. Myomo believes the use of this non-GAAP financial measure provides supplementary information for investors to use in evaluating operating performance and in comparing Myomo’s financial measures with other companies in its industry, many of which present similar non-GAAP financial measures. Adjusted EBITDA is EBITDA adjusted for stock-based compensation expense and loss on equity investment. This non-GAAP financial measure is not meant to be considered superior to or a substitute for results of operations prepared in accordance with GAAP, and should be viewed in conjunction with GAAP financial measures. Investors are encouraged to review the reconciliation of this non-GAAP measure to its most directly comparable GAAP financial measure. A reconciliation of GAAP to the non-GAAP financial measures has been provided in the tables included as part of this press release.

About Myomo

Myomo, Inc. is a wearable medical robotics company that offers improved arm and hand function for those suffering from neurological disorders and upper-limb paralysis. Myomo develops and markets the MyoPro product line. MyoPro is a powered upper-limb orthosis designed to support the arm and restore function to the weakened or paralyzed arms of certain patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury or other neuromuscular disease or injury. It is currently the only marketed device that, sensing a patient’s own EMG signals through non-invasive sensors on the arm, can restore an individual’s ability to perform activities of daily living, including feeding themselves, carrying objects and doing household tasks. Many are able to return to work, live independently and reduce their cost of care. Myomo is headquartered in Boston, Massachusetts, with sales and clinical professionals across the U.S. and representatives internationally. For more information, please visit www.myomo.com.

Forward-Looking Statements

This press release contains forward-looking statements regarding the Company’s future business expectations, including expectations for fourth quarter and full year 2024 revenue, as well as expectations regarding achieving operating cash flow breakeven and approaching Adjusted EBITDA breakeven in the fourth quarter of 2024, which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are only predictions and may differ materially from actual results due to a variety of factors.

These factors include, among other things:

• our ability to obtain sufficient reimbursement from third-party payers for our products;
• our ability to navigate factors both within and outside our control to grow revenues sufficiently to achieve operating cash flow breakeven on a quarterly basis;
• our revenue concentration with Medicare and with a particular insurance payer as a result of focusing our efforts on patients with insurers who have previously reimbursed for the MyoPro;
• our ability to continue normal operations and patient interactions without supply chain disruption in order to deliver and fit our custom-fabricated devices;
• our marketing and commercialization efforts;
• our dependence upon external sources for the financing of our operations, to the extent that we do not achieve or maintain cash flow breakeven;
• our ability to obtain and maintain our strategic collaborations and to realize the intended results of such collaborations;
• our ability to effectively execute our business plan and scale up our operations;
• our expectations as to our product development programs, including improving our existing products and developing new products;
• our ability to maintain and grow our reputation and to achieve and maintain the market acceptance of our products;
• our expectations as to our clinical research program and clinical results;
• our ability to maintain adequate protection of our intellectual property and to avoid violation of the intellectual property rights of others;
• our ability to gain and maintain regulatory approvals;
• our ability to compete and succeed in a highly competitive and evolving industry; and
• general market, economic, environmental and social factors that may affect the evaluation, fitting, delivery and sale of our products to patients.

More information about these and other factors that potentially could affect our financial results is included in Myomo’s filings with the Securities and Exchange Commission, including those contained in the risk factors section of the Company’s annual report on Form 10-K, quarterly reports on Form 10-Q and other filings with the Commission. The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. Although the forward-looking statements in this release of financial information are based on our beliefs, assumptions and expectations, taking into account all information currently available to us, we cannot guarantee future transactions, results, performance, achievements or outcomes. No assurance can be made to any investor by anyone that the expectations reflected in our forward-looking statements will be attained, or that deviations from them will not be material or adverse. The Company disclaims any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.

 

MYOMO, INC.

 CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)

 

 

 

For the Three Months ended

 

 

For the Nine Months Ended

 

 

 

September 30,

 

 

September 30,

 

 

 

2024

 

 

2023

 

 

2024

 

 

2023

 

Revenue

 

 

 

 

 

 

 

 

 

 

 

 

Product revenue

 

$

9,207,586

 

 

$

5,029,523

 

 

$

20,482,742

 

 

$

12,719,855

 

License revenue

 

 

—

 

 

 

50,000

 

 

 

—

 

 

 

1,764,920

 

 

 

 

9,207,586

 

 

 

5,079,523

 

 

 

20,482,742

 

 

 

14,484,775

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of revenue

 

 

2,262,031

 

 

 

1,590,675

 

 

 

5,912,632

 

 

 

4,407,270

 

Gross profit

 

 

6,945,555

 

 

 

3,488,848

 

 

 

14,570,110

 

 

 

10,077,505

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

 

1,248,870

 

 

 

717,256

 

 

 

3,212,309

 

 

 

1,758,480

 

Selling, clinical and marketing

 

 

3,401,182

 

 

 

2,387,090

 

 

 

8,540,161

 

 

 

6,689,578

 

General and administrative

 

 

3,253,056

 

 

 

2,408,871

 

 

 

8,779,024

 

 

 

7,427,818

 

 

 

 

7,903,108

 

 

 

5,513,217

 

 

 

20,531,494

 

 

 

15,875,876

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss from operations

 

 

(957,553

)

 

 

(2,024,369

)

 

 

(5,961,384

)

 

 

(5,798,371

)

 

 

 

 

 

 

 

 

 

 

 

 

 

Other (income) expense, net

 

 

 

 

 

 

 

 

 

 

 

 

Interest income, net

 

 

(76,020

)

 

 

(112,300

)

 

 

(318,555

)

 

 

(302,053

)

Other expense, net

 

 

—

 

 

 

467

 

 

 

—

 

 

 

6,098

 

Loss on equity investment

 

 

—

 

 

 

70,124

 

 

 

—

 

 

 

99,840

 

 

 

 

(76,020

)

 

 

(41,709

)

 

 

(318,555

)

 

 

(196,115

)

Loss before income taxes

 

 

(881,533

)

 

 

(1,982,660

)

 

 

(5,642,829

)

 

 

(5,602,256

)

Income tax expense

 

 

84,876

 

 

 

46,356

 

 

 

280,819

 

 

 

85,204

 

Net loss

 

$

(966,409

)

 

$

(2,029,016

)

 

$

(5,923,648

)

 

$

(5,687,461

)

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average number of common shares outstanding:

 

 

 

 

 

 

 

 

 

 

 

 

Basic and diluted

 

 

37,950,515

 

 

 

35,266,361

 

 

 

37,359,366

 

 

 

27,537,357

 

Net loss per share attributable to common stockholders

 

 

 

 

 

 

 

 

 

 

 

 

Basic and diluted

 

$

(0.03

)

 

$

(0.06

)

 

$

(0.16

)

 

$

(0.21

)

 

 

MYOMO, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

 

 

 

September 30,

 

 

December 31,

 

 

 

2024

 

 

2023

 

 

 

(unaudited)

 

 

 

 

ASSETS

 

 

 

 

 

 

Current Assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

6,622,675

 

 

$

6,871,306

 

Short-term investments

 

 

—

 

 

 

1,994,662

 

Accounts receivable, net

 

 

3,729,387

 

 

 

2,382,658

 

Inventories, net

 

 

3,383,513

 

 

 

1,803,507

 

Prepaid expenses and other current assets

 

 

968,569

 

 

 

598,850

 

Total Current Assets

 

 

14,704,144

 

 

 

13,650,983

 

Restricted cash

 

 

375,000

 

 

 

—

 

Operating lease assets with right of use

 

 

466,962

 

 

 

663,554

 

Equipment, net

 

 

561,325

 

 

 

175,794

 

Other assets

 

 

205,440

 

 

 

91,237

 

Total Assets

 

$

16,312,871

 

 

$

14,581,568

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

 

 

 

Current Liabilities:

 

 

 

 

 

 

Accounts payable and accrued expenses

 

 

6,448,076

 

 

 

4,885,944

 

Current operating lease liability

 

 

205,464

 

 

 

486,143

 

Income taxes payable

 

 

305,861

 

 

 

96,461

 

Deferred revenue

 

 

31,971

 

 

 

8,510

 

Total Current Liabilities

 

 

6,991,372

 

 

 

5,477,058

 

Non-current operating lease liability

 

 

29,165

 

 

 

115,160

 

Total Liabilities

 

 

7,020,537

 

 

 

5,592,218

 

Commitments and Contingencies

 

 

—

 

 

 

—

 

Stockholders’ Equity:

 

 

 

 

 

 

Preferred stock

 

 

—

 

 

 

—

 

Common stock

 

 

3,026

 

 

 

2,715

 

Additional paid-in capital

 

 

111,754,495

 

 

 

105,840,239

 

Accumulated other comprehensive income

 

 

395,734

 

 

 

83,669

 

Accumulated deficit

 

 

(102,854,457

)

 

 

(96,930,809

)

Treasury stock, at cost

 

 

(6,464

)

 

 

(6,464

)

Total Stockholders’ Equity

 

 

9,292,334

 

 

 

8,989,350

 

Total Liabilities and Stockholders’ Equity

 

$

16,312,871

 

 

$

14,581,568

 

 

MYOMO, INC.

 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)

 

For the Nine Months Ended September 30,

 

2024

 

 

2023

 

CASH FLOWS FROM OPERATING ACTIVITIES

 

 

 

 

 

 

Net loss

 

$

(5,923,648

)

 

$

(5,687,461

)

Adjustments to reconcile net loss to net cash used in operations:

 

 

 

 

 

 

Depreciation

 

 

114,346

 

 

 

136,416

 

Stock-based compensation

 

 

552,580

 

 

 

781,513

 

Accretion of discount on short-term investments

 

 

(108,999

)

 

 

—

 

Credit losses

 

 

5,257

 

 

 

12,626

 

Loss on equity investment

 

 

—

 

 

 

99,840

 

Amortization of right-of-use assets

 

 

196,592

 

 

 

301,053

 

Other non-cash charges

 

 

84,180

 

 

 

(49,271

)

Changes in operating assets and liabilities:

 

 

 

 

 

 

Accounts receivable

 

 

(1,116,352

)

 

 

(625,596

)

Inventories

 

 

(1,573,193

)

 

 

(90,100

)

Prepaid expenses and other current assets

 

 

(614,951

)

 

 

(439,584

)

Other assets

 

 

(16,640

)

 

 

19,797

 

Accounts payable and accrued expenses

 

 

1,895,795

 

 

 

2,141,978

 

Income taxes payable

 

 

202,137

 

 

 

(74,944

)

Operating lease liabilities

 

 

(366,675

)

 

 

(352,820

)

Deferred revenue

 

 

23,460

 

 

 

9,533

 

Net cash used in operating activities

 

 

(6,655,632

)

 

 

(3,817,020

)

CASH USED IN INVESTING ACTIVITIES

 

 

1,613,180

 

 

 

(4,324,017

)

CASH PROVIDED BY FINANCING ACTIVITIES

 

 

5,162,409

 

 

 

9,713,426

 

Effect of foreign exchange rate changes on cash

 

 

6,412

 

 

 

(6,610

)

 

 

 

 

 

 

 

'Net (decrease) increase in cash and cash equivalents and restricted cash

 

 

126,369

 

 

 

1,565,780

 

 

 

 

 

 

 

 

Cash, cash equivalents and restricted cash, beginning of period

 

 

6,871,306

 

 

 

5,345,967

 

 

 

 

 

 

 

 

Cash, cash equivalents and restricted cash, end of period

 

$

6,997,675

 

 

$

6,911,747

 

 

 

MYOMO, INC.

RECONCILIATION OF GAAP NET LOSS TO ADJUSTED EBITDA

(unaudited)

 

 

 

For the Three Months Ended September 30,

 

 

For the Nine Months Ended September 30,

 

 

 

2024

 

 

2023

 

 

2024

 

 

2023

 

GAAP net loss

 

$

(966,409

)

 

$

(2,029,016

)

 

$

(5,923,648

)

 

$

(5,687,461

)

Adjustments to reconcile to Adjusted EBITDA:

 

 

 

 

 

 

 

 

 

 

 

 

Interest income

 

 

(76,020

)

 

 

(112,300

)

 

 

(318,555

)

 

 

(302,053

)

Depreciation expense

 

 

48,682

 

 

 

35,794

 

 

 

114,346

 

 

 

136,416

 

Stock-based compensation

 

 

324,185

 

 

 

330,394

 

 

 

552,580

 

 

 

781,513

 

Loss on investment in minority interest

 

 

—

 

 

 

70,124

 

 

 

—

 

 

 

99,840

 

Income tax expense

 

 

84,876

 

 

 

46,356

 

 

 

280,819

 

 

 

85,204

 

Adjusted EBITDA

 

$

(584,686

)

 

$

(1,658,648

)

 

$

(5,294,458

)

 

$

(4,886,541

)

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20241106431006/en/

For Myomo: [e-mail] Investor Relations: Kim Sutton Golodetz Alliance Advisors IR [e-mail] 212-838-3777